Table 1.
Classification of main criteria and sub criteria based on frequency in reviewed Studies (in pre-Assessment and also in Assessment phase)
| Main Criteria | Health Outcomes | Disease and Target Population | Alternatives | Economic Aspects | Evidence | Other Factors | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sub criteria | Frequency | Sub criteria | Frequency | Sub criteria | Frequency | Sub criteria | Frequency | Sub criteria | Frequency | Sub criteria | Frequency | |
| 1 | Health effects/benefits | 8 | Disease severity | 12 | Number of alternatives | 2 | Cost-effectiveness | 15 | Quality of evidence | 4 | Issues related to health system | 11 |
| 2 | Clinical effects/benefits | 7 | Disease burden | 8 | Availability of alternative | 1 | Costs | 11 | Number of evidence | 3 | Sporadic sub criteria | 11 |
| 3 | Efficacy/effectiveness | 4 | Target population age | 7 | Limitations of comparative interventions | 1 | Budget impact | 10 | Evidence relevance and validity | 1 | Political, social and moral issues | 10 |
| 4 | Individual health benefits | 3 | Population size | 3 | Lack of alternatives | 1 | Economic impact | 6 | Power of evidence | 1 | Benefits of beneficiaries | 6 |
| 5 | Safety | 3 | Number of potential beneficiaries | 3 | - | - | Poverty Reduction | 4 | Completeness and consistency of reporting evidence | 1 | Issues related to patients | 5 |
| 6 | Quality of life | 1 | Characteristics of target social groups for intervention | 2 | - | - | Value for money | 2 | Adherence to requirements of decision making body | 1 | Issues related to decision-making conditions | 5 |
| 7 | Potential changes in health consequences | 1 | Number of patients | 2 | - | - | Financial opportunity/consequences | 2 | - | - | Fairness and equity | 4 |
| 8 | The effect of assessment on reduction of uncertainty | 1 | Effect of technology on reduction of disease prevalence and incidence | 1 | - | - | Economic productivity | 2 | - | - | - | - |
| 9 | Marginal benefits | 1 | Disease impacts | 1 | - | - | Financial protection | 1 | - | - | - | - |
| 10 | Ability to reduce own health risk | 1 | Effect on targeted groups | 1 | - | - | Subsidized Payment | 1 | - | - | ||
| 11 | Potential to extend life | 1 | Size of vulnerable population | 1 | - | - | Society interest and demand | 1 | - | - | - | - |
| 12 | Potential to detect a condition which, if treated early, averts costs in the future | 1 | - | - | - | - | Technology price and sale volume | 1 | - | - | - | - |